DCT

2:26-cv-08690

Translate Bio Inc v. Moderna Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-08690, D.N.J., 07/14/2026
  • Venue Allegations: Plaintiffs allege venue is proper in the District of New Jersey because Defendant Moderna has a regular and established place of business in the district, specifically a facility in Princeton, NJ, and because it uses, offers for sale, and/or sells its Accused Products within the district.
  • Core Dispute: Plaintiffs allege that Defendant's mRNA vaccines-including its COVID-19 and RSV vaccines-infringe ten U.S. patents related to messenger RNA (mRNA) delivery methods, lipid nanoparticle (LNP) compositions, and mRNA purity standards.
  • Technical Context: The technology relates to the formulation and delivery of mRNA therapeutics using lipid nanoparticles, a field that gained immense market and public health significance with the development of vaccines for COVID-19.
  • Key Procedural History: The complaint notes a 2018 collaboration between Plaintiff Translate Bio and Sanofi to develop mRNA vaccines, which was followed by Sanofi's acquisition of Translate Bio in 2021. Several of the asserted patents have undergone Certificates of Correction, which may be relevant for claim construction.

Case Timeline

Date Event
2011-06-08 Priority Date for '754, '618, '734, '044, '764 Patents
2012-03-29 Priority Date for '005, '885 Patents
2013-03-14 Priority Date for '554 Patent
2014-04-25 Priority Date for '269, '841 Patents
2017-12-26 '269 Patent Issued
2019-03-26 '754 Patent Issued
2019-09-17 '618 Patent Issued
2020-03-16 First dose of Moderna's COVID-19 vaccine administered in clinical trial
2020-12-18 FDA grants Emergency Use Authorization (EUA) for Moderna COVID-19 Vaccine
2021-07-13 '841 Patent Issued
2022-01-31 FDA approves SPIKEVAX®
2022-04-05 '734 Patent Issued
2022-05-24 '044 Patent Issued
2023-01-10 '764 Patent Issued
2024-06-14 FDA approves MRESVIA®
2025-05-30 FDA approves MNEXSPIKE®
2025-06-17 '005 Patent Issued
2025-11-04 '885 Patent Issued
2026-03-17 '554 Patent Issued
2026-07-14 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,238,754 - "Lipid Nanoparticle Compositions and Methods for mRNA Delivery"

The Invention Explained

  • Problem Addressed: The patent's background section identifies the difficulty of using mRNA for gene therapy due to its instability and the challenge of achieving sustained, therapeutic levels of secreted proteins in the blood using prior nucleic acid delivery methods (e.g., '754 Patent, col. 2:1-9; '754 Patent, col. 2:26-40).
  • The Patented Solution: The invention claims to solve this problem by providing a method for delivering mRNA encapsulated in a lipid nanoparticle (LNP). This encapsulation is designed to create a "depot effect" where target cells produce and secrete the encoded protein into the circulatory system for a sustained period, specifically being detectable in serum for at least 72 hours after administration ('754 Patent, abstract; '754 Patent, col. 3:1-6; '754 Patent, claim 1).
  • Technical Importance: This method represented an approach to overcome mRNA's short half-life, potentially enabling its use for therapeutic protein replacement where sustained in vivo protein levels are required ('754 Patent, col. 2:52-64).

Key Claims at a Glance

  • The complaint asserts independent claim 1 ('754 Patent, claim 1; Compl. ¶37).
  • The essential elements of Claim 1 are:
    • A method for delivery of messenger RNA (mRNA) for in vivo production of a protein or a peptide,
    • comprising administering to a human, a composition comprising an mRNA that encodes a protein or a peptide,
    • wherein the mRNA is encapsulated within a lipid nanoparticle,
    • and wherein the administering of the composition results in expression of the protein or the peptide encoded by the mRNA that is detectable in serum at least 72 hours after administration,
    • wherein the lipid nanoparticle comprises one or more PEG-modified lipids.
  • The complaint reserves the right to assert other claims (Compl. ¶3).

U.S. Patent No. 10,413,618 - "Lipid Nanoparticle Compositions and Methods for mRNA Delivery"

The Invention Explained

  • Problem Addressed: Similar to the '754 Patent, the '618 Patent addresses the challenge that mRNA is far less stable than DNA and that prior methods failed to produce sustained, therapeutic levels of secreted proteins in vivo ('618 Patent, col. 2:1-9; '618 Patent, col. 2:28-42).
  • The Patented Solution: The '618 Patent describes a nearly identical solution to the '754 Patent: a method of delivering mRNA encapsulated in an LNP to create a "depot effect." This method results in the sustained expression of the encoded protein, which is claimed to be detectable in serum for at least 72 hours after administration ('618 Patent, abstract; '618 Patent, col. 3:1-7; '618 Patent, claim 1).
  • Technical Importance: The technology aimed to make mRNA a viable platform for therapeutic protein replacement by enabling sustained in vivo expression, a key limitation of earlier RNA-based approaches ('618 Patent, col. 2:54-66).

Key Claims at a Glance

  • The complaint asserts independent claim 1 ('618 Patent, claim 1; Compl. ¶41).
  • The essential elements of Claim 1 are:
    • A method for delivery of messenger RNA (mRNA) for in vivo production of a protein,
    • comprising administering, to a human, a composition comprising an mRNA that encodes the protein,
    • wherein the mRNA is encapsulated within a lipid nanoparticle,
    • wherein the administering of the composition results in expression of the protein encoded by the mRNA that is detectable in serum at least 72 hours after administration,
    • and wherein the lipid nanoparticle comprises one or more PEG-modified lipids.
  • The complaint reserves the right to assert other claims (Compl. ¶3).

U.S. Patent No. 11,291,734 ('734 Patent) - "Lipid Nanoparticle Compositions and Methods for mRNA Delivery"

  • Technology Synopsis: This patent also covers methods for delivering LNP-encapsulated mRNA to achieve sustained protein expression. It is distinguished by claiming a functional outcome where the protein is detectable in a target tissue for at least 48 hours after administration (Compl. ¶44; '734 Patent, claim 1).
  • Asserted Claims: The complaint asserts independent claim 1 (Compl. ¶45).
  • Accused Features: The administration of Moderna's SPIKEVAX®, MNEXSPIKE®, and MRESVIA® vaccines is alleged to infringe by producing the encoded antigen in target tissue for at least 48 hours (Compl. ¶87; Compl. ¶93; Compl. ¶100; Compl. ¶107).

U.S. Patent No. 11,338,044 ('044 Patent) - "Lipid Nanoparticle Compositions and Methods for mRNA Delivery"

  • Technology Synopsis: This patent claims methods of mRNA delivery using LNPs with specific compositional ratios. The LNP must comprise a PEG-modified lipid, a cationic lipid, a non-cationic lipid, and cholesterol, each at a molar ratio greater than a specified percentage of the total lipids (Compl. ¶49; '044 Patent, claim 1).
  • Asserted Claims: The complaint asserts independent claim 1 (Compl. ¶49).
  • Accused Features: The LNP formulations in Moderna's vaccines, which contain specific ratios of these four lipid types, are alleged to meet the claimed compositional requirements (Compl. ¶87; Compl. ¶112; Compl. ¶117; Compl. ¶122).

U.S. Patent No. 11,547,764 ('764 Patent) - "Lipid Nanoparticle Compositions and Methods for mRNA Delivery"

  • Technology Synopsis: This patent claims a composition comprising an LNP-encapsulated mRNA. The LNP must be smaller than 150 nm and meet specific lipid molar ratios, while the mRNA itself must comprise a 5'-UTR, a 3'-UTR, a 5' cap structure, and a poly A tail (Compl. ¶53; '764 Patent, claim 1).
  • Asserted Claims: The complaint asserts independent claim 1 (Compl. ¶53).
  • Accused Features: The vaccines themselves are alleged to be infringing compositions, containing mRNA with the claimed structural elements encapsulated in LNPs that are smaller than 150 nm and possess the claimed lipid molar ratios (Compl. ¶109; Compl. ¶111; Compl. ¶112; Compl. ¶113).

U.S. Patent No. 12,331,005 ('005 Patent) - "Ionizable Cationic Lipids"

  • Technology Synopsis: This patent claims an LNP composition containing a specific ionizable cationic lipid defined by a chemical Markush structure. The structure includes defined variables for alkyl/alkenyl chains (R1, R2, L1, L2) and linkers (m, n, o) (Compl. ¶57; '005 Patent, claim 1).
  • Asserted Claims: The complaint asserts independent claim 1 (Compl. ¶57).
  • Accused Features: The accused vaccines contain the ionizable cationic lipid SM-102, which Plaintiffs allege has a chemical structure that falls within the scope of the patent's claimed Markush structure (Compl. ¶124; Compl. ¶129; Compl. ¶131).

U.S. Patent No. 12,459,885 ('885 Patent) - "Ionizable Cationic Lipids"

  • Technology Synopsis: Similar to the '005 patent, this patent claims an LNP with a cationic lipid defined by a Markush structure. The structure is nearly identical to that in the '005 patent but with slightly different definitions for the variables (e.g., 'o is zero; and n is zero or one') (Compl. ¶61; '885 Patent, claim 1).
  • Asserted Claims: The complaint asserts independent claim 1 (Compl. ¶61).
  • Accused Features: The lipid SM-102 in Moderna's vaccines is alleged to meet the limitations of the claimed chemical structure (Compl. ¶124; Compl. ¶129; Compl. ¶131; Compl. ¶132).

U.S. Patent No. 9,850,269 ('269 Patent) - "Methods for Purification of Messenger RNA"

  • Technology Synopsis: This patent claims a composition of in vitro synthesized mRNA characterized by its purity, specifically containing less than 1% of prematurely aborted RNA sequences and/or enzyme reagents from the synthesis process (Compl. ¶65; '269 Patent, claim 14).
  • Asserted Claims: The complaint asserts independent claim 14 (Compl. ¶65).
  • Accused Features: The purified mRNA in Moderna's vaccines is alleged, by virtue of Moderna's purification methods, to meet this purity threshold (Compl. ¶133; Compl. ¶136; Compl. ¶137; Compl. ¶138).

U.S. Patent No. 11,059,841 ('841 Patent) - "Methods for Purification of Messenger RNA"

  • Technology Synopsis: This patent is similar to the '269 patent but claims a slightly less stringent purity standard: a composition of in vitro synthesized mRNA containing less than 5% of prematurely aborted RNA sequences and/or enzyme reagents (Compl. ¶69; '841 Patent, claim 18).
  • Asserted Claims: The complaint asserts independent claim 18 (Compl. ¶69).
  • Accused Features: The purified mRNA in Moderna's vaccines is alleged to meet the <5% impurity threshold (Compl. ¶133; Compl. ¶136; Compl. ¶137; Compl. ¶138).

U.S. Patent No. 12,577,554 ('554 Patent) - "Methods for Purification of Messenger RNA"

  • Technology Synopsis: This patent claims a pharmaceutically acceptable composition comprising purified mRNA that is (a) substantially free of prematurely aborted RNA sequences of less than 15 bases, (b) comprises one or more 1-methylpseudouracil nucleosides, and (c) is suitable for administration to a human (Compl. ¶73; '554 Patent, claim 1).
  • Asserted Claims: The complaint asserts independent claim 1 (Compl. ¶73).
  • Accused Features: The mRNA in Moderna's vaccines is alleged to be purified to this level, contain the specified nucleoside modification, and be suitable for human use (Compl. ¶134; Compl. ¶139; Compl. ¶140; Compl. ¶141).

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Moderna's COVID-19 vaccines, SPIKEVAX® and MNEXSPIKE®, and its RSV vaccine, MRESVIA® (collectively, the "Accused Products") (Compl. ¶2).

Functionality and Market Context

  • The Accused Products are mRNA-based vaccines that deliver nucleoside-modified mRNA, which encodes a viral antigen, to human cells (Compl. ¶90; Compl. ¶91; Compl. ¶97; Compl. ¶104). The mRNA is encapsulated in a lipid nanoparticle (LNP) delivery system that includes four lipids, one of which is the ionizable cationic lipid SM-102 (Compl. ¶2; Compl. ¶81; Compl. ¶83; Compl. ¶85). Upon administration, the LNP facilitates delivery of the mRNA into host cells, which then express the antigen, eliciting an immune response (Compl. ¶91). An excerpt from the SPIKEVAX prescribing information shows instructions to "Administer SPIKEVAX intramuscularly" (Compl. ¶89).
  • The complaint alleges the Accused Products have been highly successful, with Moderna enjoying net sales of over $1.8 billion globally in 2025 alone (Compl. ¶86).

IV. Analysis of Infringement Allegations

'754 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for delivery of messenger RNA (mRNA) for in vivo production of a protein or a peptide, comprising administering to a human, a composition... Moderna is alleged to induce infringement by instructing healthcare professionals to administer the Accused Products to human patients. ¶88 col. 43:1-4
...comprising an mRNA that encodes a protein or a peptide... The Accused Products contain mRNA encoding viral antigens, such as the COVID-19 spike glycoprotein or the RSV F glycoprotein. ¶90; ¶97; ¶104 col. 43:4-5
...wherein the mRNA is encapsulated within a lipid nanoparticle... The mRNA in the Accused Products is formulated in and delivered by lipid nanoparticles (LNPs). ¶91; ¶98; ¶105 col. 43:6-7
...wherein the administering of the composition results in expression of the protein or the peptide encoded by the mRNA that is detectable in serum at least 72 hours after administration... On information and belief, administration of the Accused Products results in the expression of the encoded protein, which is detectable in the patient's serum for at least 72 hours. ¶92; ¶99; ¶106 col. 43:7-11
...wherein the lipid nanoparticle comprises one or more PEG-modified lipids. The LNPs in the Accused Products contain the PEG-modified lipid PEG 2000 DMG. ¶94; ¶101; ¶108 col. 43:11-13

'618 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for delivery of messenger RNA (mRNA) for in vivo production of a protein, comprising administering, to a human, a composition... Moderna is alleged to induce infringement by instructing healthcare professionals to administer the Accused Products to human patients. ¶88 col. 44:1-3
...comprising an mRNA that encodes the protein... The Accused Products contain mRNA encoding viral antigens, such as the COVID-19 spike glycoprotein or the RSV F glycoprotein. ¶90; ¶97; ¶104 col. 44:3-4
...wherein the mRNA is encapsulated within a lipid nanoparticle... The mRNA in the Accused Products is formulated in and delivered by lipid nanoparticles (LNPs). ¶91; ¶98; ¶105 col. 44:4-5
...wherein the administering of the composition results in expression of the protein encoded by the mRNA that is detectable in serum at least 72 hours after administration... On information and belief, administration of the Accused Products results in the expression of the encoded protein, which is detectable in the patient's serum for at least 72 hours. ¶92; ¶99; ¶106 col. 44:5-9
...and wherein the lipid nanoparticle comprises one or more PEG-modified lipids. The LNPs in the Accused Products contain the PEG-modified lipid PEG 2000 DMG. ¶94; ¶101; ¶108 col. 44:9-11

Identified Points of Contention

  • Scope and Evidentiary Questions: For the '754 and '618 patents, a central point of contention will be the functional limitation requiring the encoded protein to be "detectable in serum at least 72 hours after administration" (Compl. ¶37; Compl. ¶41). The case may turn on what level of protein is considered "detectable" under the patent's scope and whether Plaintiffs can produce sufficient evidence (e.g., from clinical trial data) to prove that the Accused Products meet this specific pharmacokinetic profile in the serum of human patients.
  • Technical Questions: For the patents claiming specific LNP compositions (e.g., '044, '764, '005, '885 Patents), the dispute will likely involve a detailed technical comparison between the claimed lipid ratios and chemical structures and the actual composition of Moderna's vaccines. The complaint provides the alleged structure of SM-102, setting up a direct comparison to the Markush structures claimed in the '005 and '885 patents (Compl. ¶129). This raises the question of whether the specific variables of the SM-102 lipid (e.g., its alkyl chain lengths and substitutions) fall within the literal scope of the claims.
  • Infringement Theory Questions: For the method claims (e.g., '754, '618, '734, '044 Patents), the infringement theory relies heavily on inducement (Compl. ¶149). This raises the legal question of whether Moderna's prescribing information instructs users to perform every limitation of the claims, including the functional outcomes (e.g., protein detectable for 72 hours), or merely instructs administration without guaranteeing the claimed result.

V. Key Claim Terms for Construction

  • The Term: "detectable in serum at least 72 hours after administration"
  • Context and Importance: This term, appearing in the independent claims of the '754 and '618 patents, is the central functional limitation defining the invention's "depot effect." Its construction will be critical for infringement, as it sets the standard for the duration and location of protein expression that the Accused Products must be shown to achieve. Practitioners may focus on this term because it requires specific pharmacokinetic evidence that will be a key point of proof.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification describes detection via standard methods like ELISA ('754 Patent, col. 28:35-41). Plaintiffs may argue that "detectable" means any level measurable by such conventional assays that is statistically significant above a pre-dose baseline, as shown in the patent's own experimental data figures ('754 Patent, FIG. 7).
    • Evidence for a Narrower Interpretation: Defendants may argue that the term implies a "therapeutic level" of the protein, as the patent repeatedly discusses the goal of achieving "therapeutic levels of secreted proteins" ('754 Patent, col. 3:4-5; '754 Patent, col. 3:37-38). They may also point to specific quantities shown in the patent's examples as defining the threshold for what is "detectable" in a patentably distinct manner.
  • The Term: "lipid nanoparticle"
  • Context and Importance: The scope of this term is fundamental to all asserted patents. While the Accused Products use LNPs, the specific definition of what constitutes a "lipid nanoparticle"-including its required and optional components-will determine if Moderna's formulation, which uses the SM-102 lipid, falls within the claims.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification provides a broad definition, stating a lipid nanoparticle is a transfer vehicle comprising "one or more lipids (e.g., cationic lipids, non-cationic lipids, and PEG-modified lipids)" ('754 Patent, col. 15:8-11). Plaintiffs may argue this allows for a wide variety of lipid combinations.
    • Evidence for a Narrower Interpretation: The specification provides several specific exemplary formulations (e.g., "C12-200, DOPE, chol, DMG-PEG2K at a molar ratio of 40:30:25:5") ('754 Patent, col. 19:62-65). Defendants may argue these specific embodiments limit the scope of the term, or that features of these exemplary lipids (not present in SM-102) are implicitly required.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for many of the asserted patents. Inducement is primarily based on allegations that Moderna's prescribing information, advertisements, and other materials intentionally instruct and encourage healthcare professionals to administer the Accused Products in a manner that performs the steps of the patented methods (Compl. ¶2; Compl. ¶88; Compl. ¶95; Compl. ¶102). Contributory infringement is alleged on the basis that Moderna offers to sell products which have no substantial non-infringing use and can only be used in a manner that infringes (Compl. ¶150).
  • Willful Infringement: No probative visual evidence provided in complaint.

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of induced infringement and proof: Can Plaintiffs demonstrate not only that Moderna's instructions direct the physical act of administering the vaccine, but also that this administration necessarily results in the claimed functional outcome-specifically, a protein level that is "detectable in serum at least 72 hours after administration"-thereby satisfying all limitations of the method claims?
  • A key question of claim construction and technical scope will be: How is the term "detectable" to be defined? Will it mean any scientifically measurable amount above baseline, as Plaintiffs may argue, or will it require a higher, therapeutically relevant threshold, as Defendants may contend? The resolution of this definitional dispute will directly impact the evidentiary burden for proving infringement.
  • A third core issue will be one of compositional equivalence: For the patents directed to specific LNP compositions, the case will likely turn on a detailed chemical analysis. Does Moderna's SM-102 lipid fall within the literal scope of the Markush structures claimed in the '005 and '885 patents, and does the overall LNP formulation of the Accused Products meet the specific component and ratio requirements of the '044 and '764 patents?
Loading Complaint